Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.81 |
| ▸ | NT5E | P21589 | 1/20 | 0.76 |
| ▸ | KRAS | P01116 | 2/20 | 0.76 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.75 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.71 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.65 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gtp SCHEMBL18271799 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL3333959 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376140 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL18784960 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL19691775 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL2593095 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL17367368 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL96708 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024155027-A1 | ATTENUATED SALMONELLA GALLINARUM EXPRESSING FLIC OR FLIC-HIL2 AND USE THEREOF | 주식회사 오디세우스바이오 | 2024-07-25 | — | — | WO | claimed |
| US-20240240140-A1 | ATTENUATED SALMONELLA GALLINARUM EXPRESSING FLIC OR FLIC-HIL2 AND USES THEREOF | Odysseus Bio Co., Ltd. (KR) | 2024-07-18 | — | — | US | claimed |
| US-20240218318-A1 | ATTENUATED SALMONELLA GALLINARUM STRAIN AND USE THEREOF | Odysseus Bio Co., Ltd. (KR) | 2024-07-04 | — | — | US | claimed |
| US-20240108664-A1 | TUMOR-TARGETING SALMONELLA GALLINARUM STRAIN AND USE THEREOF | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2024-04-04 | — | — | US | claimed |
| EP-4332228-A1 | ATTENUATED SALMONELLA GALLINARUM STRAIN AND USE THEREOF | Industry Foundation of Chonnam National University (KR) | 2024-03-06 | — | — | EP | claimed |
| CN-117480255-A | Attenuated salmonella gallinarum strain and use thereof | 全南大学校产学协力团 | 2024-01-30 | — | — | CN | claimed |
| CN-114324540-B | Guanosine tetraphosphoric acid electrochemical nano-enzyme sensor and preparation method thereof | 天津商业大学 | 2023-12-26 | — | — | CN | claimed |
| CN-115943211-A | Tumor-targeted salmonella gallinarum strain and application thereof | 全南大学校产学协力团 | 2023-04-07 | — | — | CN | claimed |
| CN-115844804-A | Composition for improving exogenous aging and preparation method and application thereof | 湖北省吉美化妆品有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115813803-A | Composition capable of improving skin anti-wrinkle, moisturizing and whitening effects on cell layer | 广州时光之城科技有限公司 | 2023-03-21 | — | — | CN | claimed |
| EP-1451211-A2 | COMPOSITIONS AND METHODS FOR MODULATING GUANYLYL CYCLASE SIGNALING RECEPTOR (GC-C) ACTIVITY AND FOR TREATING MENIERE'S DISEASE | University of Copenhagen (DK) | 2004-09-01 | — | — | EP | claimed |
| US-20040152868-A1 | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease | UNIVERSITY OF COPENHAGEN (DK) | 2004-08-05 | — | — | US | claimed |
| US-6562801-B1 | PpGpp and pppGpp as immunomodulatory agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-05-13 | — | — | US | claimed |
| US-20030039657-A1 | Inducible vaccines | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-02-27 | — | — | US | claimed |
| WO-2002079235-A2 | COMPOSITIONS AND METHODS FOR MODULATING GUANYLYL CYCLASE SIGNALING RECEPTOR (GC-C) ACTIVITY AND FOR TREATING MENIERE'S DISEASE | UNIVERSITY OF COPENHAGEN (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2000062817-A2 | INDUCIBLE VACCINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-10-26 | — | — | WO | claimed |
| WO-2000062803-A2 | ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-10-26 | — | — | WO | claimed |
| EP-1005327-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152868-A1 | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease | PDE7A, PDE6C, PDE9A | TGM2 1239/4885NT5E 397/4885KRAS 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.